Treatment of Haemophilia A Without Inhibitors: Real‐World Treatment Patterns and Clinical Outcomes in the US
Haemophilia · 2026
DOI: 10.1111/hae.70271 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Haemophilia, 2026. Verfasst von Allison P Wheeler und 14 weiteren Autor:innen. Beteiligte Einrichtung: Washington Center for Bleeding Disorders, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Introduction
Despite available prophylactic therapies for haemophilia A, breakthrough bleeding and consequent pain and joint damage still occur.
Aim
To provide insights into the unmet treatment needs of people with moderate‐to‐severe haemophilia A in the US.
Methods
For this descriptive, observational cohort study, eligible participants diagnosed with moderate‐to‐severe haemophilia A were enrolled in the PicnicHealth database on or before 3 October 2022. Three patient groups were established to identify: (1) treatment patterns; (2) clinical outcomes by therapy class (standard half‐life [SHL] factor VIII [FVIII]; extended half‐life FVIII [EHL]; emicizumab); (3) health‐related quality of life (HRQoL) using the Patient‐Reported Outcomes Measuring Instruments System (PROMIS)‐29 survey and a supplemental pain survey. Patients switching treatment classes were included in multiple treatment groups.
Results
Of 211 participants in the ‘treatment patterns population’, 123 (58.3%) used SHL FVIII prophylaxis, 81 (38.4%) EHL FVIII prophylaxis, and 83 (39.3%) emicizumab prophylaxis. In the ‘clinical outcomes population’, 63 participants (70.8%) receiving SHL, 43 (61.4%) EHL and 36 (62.1%) emicizumab had ≥1 bleed at Year 1. Pain‐related events within the past year occurred in 18 (12.8%), 16 (18.2%) and 10 (12.2%) participants, respectively. The most frequent patient‐reported symptoms were ‘sleep disturbance’ (84.5%), ‘inability to participate in social roles and activities’ (69.7%) and ‘fatigue’ (66.9%). The most impacted PROMIS scores were anxiety and pain interference.
Conclusion
Regardless of the prophylaxis product class used, most participants experienced ≥1 bleeding event per year and reduced QoL. Further treatment optimisation may be needed to prevent bleeding episodes and improve patient QoL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Washington Center for Bleeding Disorders, Seattle, Washington, USA.
- Department of Paediatric Haematology-Oncology and Haematology-Oncology, University of Washington, Seattle, Washington, USA.
- University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
- Division of Haematology/Oncology, Children's Mercy Kansas City, Kansas City, Missouri, USA.
- Arnold Palmer Hospital For Children, Orlando, Florida, USA.
- Sanofi, Gentilly, France.
Förderung
- Sanofi
Zitieren
APA
Wheeler, A. P., Amos, L. E., Gupta, S., Bozzi, S., Miles, G., Hawaldar, K., Wilson, A., Hanson, G., Cibelli, E., Wilson, A., Umarje, S., Tardy, A. L., Dumont, J., Neill, G., & Arnaud, A. (2026). Treatment of Haemophilia A Without Inhibitors: Real‐World Treatment Patterns and Clinical Outcomes in the US. Haemophilia. https://doi.org/10.1111/hae.70271
Vancouver
Wheeler AP, Amos LE, Gupta S, Bozzi S, Miles G, Hawaldar K, et al. Treatment of Haemophilia A Without Inhibitors: Real‐World Treatment Patterns and Clinical Outcomes in the US. Haemophilia. 2026. doi:10.1111/hae.70271
BibTeX
@article{Wheeler2026,
author = {Wheeler, Allison P and Amos, Lauren E and Gupta, Shveta and Bozzi, Sylvie and Miles, Gandarvaka and Hawaldar, Kalyani and Wilson, Andrew and Hanson, Gillian and Cibelli, Emily and Wilson, Amanda and Umarje, Siddhi and Tardy, Anne-Laure and Dumont, Jennifer and Neill, Graham and Arnaud, Alix},
title = {Treatment of Haemophilia A Without Inhibitors: Real‐World Treatment Patterns and Clinical Outcomes in the US},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70271}
}
EUVIMED